Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sells 11,337 Shares of Stock

TG Therapeutics, Inc. (NASDAQ:TGTX) CFO Sean A. Power sold 11,337 shares of TG Therapeutics stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. The trade was a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

TG Therapeutics Stock Performance

Shares of NASDAQ TGTX remained flat at $28.00 during trading on Tuesday. 2,930,795 shares of the company’s stock were exchanged, compared to its average volume of 2,870,394. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The business’s 50 day moving average is $31.26 and its 200 day moving average is $25.16. The stock has a market cap of $4.36 billion, a PE ratio of -279.97 and a beta of 2.24. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.73 EPS. Equities analysts anticipate that TG Therapeutics, Inc. will post 0.17 earnings per share for the current year.

Hedge Funds Weigh In On TG Therapeutics

Several large investors have recently made changes to their positions in TGTX. NBC Securities Inc. raised its holdings in TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 485 shares during the last quarter. Ashton Thomas Private Wealth LLC bought a new stake in shares of TG Therapeutics during the second quarter worth approximately $35,000. Blue Trust Inc. lifted its holdings in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 849 shares during the period. ORG Wealth Partners LLC bought a new position in TG Therapeutics in the third quarter valued at approximately $53,000. Finally, Values First Advisors Inc. bought a new position in TG Therapeutics in the third quarter valued at approximately $58,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on TGTX shares. The Goldman Sachs Group lifted their price objective on TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. StockNews.com lowered TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, December 22nd. HC Wainwright increased their price target on shares of TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price objective on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. Finally, TD Cowen began coverage on shares of TG Therapeutics in a research note on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.